Alivus Life Sciences (Formerly Glenmark Life Sciences) Allots 4,190 Shares Under ESOP

Team Finance Saathi

    07/Mar/2025

What’s Covered in the Article:

  • Details of equity share allotment under ESOP 2021
  • Impact on the company’s paid-up share capital
  • Regulatory compliance and stock exchange filings

Alivus Life Sciences Limited, previously known as Glenmark Life Sciences Limited, has announced the allotment of 4,190 equity shares of Rs. 2 each under the Glenmark Life Sciences Limited - Employee Stock Option Scheme (ESOP) 2021. The Nomination and Remuneration Committee approved this allotment in their meeting held on March 7, 2025. This move is part of the company’s ongoing strategy to incentivize and reward employees through stock options.

Impact on Paid-up Share Capital

Following the allotment of these shares, the company’s paid-up share capital has increased as follows:

  • Before allotment: 12,253,286,862 equity shares of Rs. 2 each, totaling Rs. 24,50,65,724
  • After allotment: 12,253,737,052 equity shares of Rs. 2 each, totaling Rs. 24,50,74,104

This allotment reflects a minor increase in the total equity base, which is part of the employee benefits scheme aimed at boosting employee engagement and retention.

Regulatory and Compliance Details

The SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021 require companies to provide certain details related to ESOP allotments. In this case, the company has filed the requisite statement with the exchanges in compliance with Regulation 10(b) on July 19, 2024. The details provided to the exchanges are as follows:

  • BSE Filing Number: DSC/IPO/AK/ESOP-IP/3281/2024-25
  • NSE Filing Number: NSE/LIST/42891

The equity shares allotted are identical to existing shares, and there are no lock-in restrictions placed on these shares.

Details of Allotment and Share Information

  • Shares allotted: 4,190
  • Exercise price per share: Rs. 716
  • Premium per share: Rs. 714
  • Total issued share capital after this issue: Rs. 24,50,74,104
  • ISIN number for shares: INE03Q201024
  • Shares are identical to existing shares: Yes, they rank pari passu (equal in all respects).

Conclusion

This allotment is part of the company’s efforts to reward employees under the ESOP scheme, which is a key component of Alivus Life Sciences' compensation strategy. Investors and stakeholders will see a slight increase in the total equity shares and paid-up capital, but this move aligns with the company’s overall employee engagement and long-term growth objectives.


The Upcoming IPOs in this week and coming weeks are Super Iron FoundryPDP Shipping & Projects.


The Closed IPOs are NAPS Global.


Start your Stock Market Journey and Apply in IPO by Opening Free Demat Account in Choice Broking FinX.


Join our Trading with CA Abhay Telegram Channel for regular Stock Market Trading and Investment Calls by CA Abhay Varn - SEBI Registered Research Analyst.


Join our Finance Saathi Telegram Channel for Regular Share Market, News & IPO Update.

Related News

Disclaimer

The information provided on this website is for educational and informational purposes only and should not be considered as financial advice, investment advice, or trading recommendations.

Trading in stocks, forex, commodities, cryptocurrencies, or any other financial instruments involves high risk and may not be suitable for all investors. Prices can fluctuate rapidly, and there is a possibility of losing part or all of your invested capital.

We do not guarantee any profits, returns, or outcomes from the use of our website, services, or tools. Past performance is not indicative of future results.

You are solely responsible for your investment and trading decisions. Before making any financial commitment, it is strongly recommended to consult with a qualified financial advisor or do your own research.

By accessing or using this website, you acknowledge that you have read, understood, and agree to this disclaimer. The website owners, partners, or affiliates shall not be held liable for any direct or indirect loss or damage arising from the use of information, tools, or services provided here.

onlyfans leakedonlyfan leaksonlyfans leaked videos